Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lukang-satouzhudan antibody ± osimertinib as neoadjuvant therapy in resectable EGFR-mutated NSCLC
CTR20254934Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Mar 2026; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on CTR20254934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254934.